Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.19.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Income Statement [Abstract]    
Revenues $ 1,363 $ 849
Cost of Revenues 337 265
Gross Profit 1,026 584
Operating Expenses    
Research and development 956 271
Sales and marketing 633 333
General and administrative 3,351 2,940
Acquisition related costs 137 16
Amortization of intangibles 812 804
Total Operating Expenses 5,889 4,364
Loss from Operations (4,863) (3,780)
Other Income (Expense)    
Interest expense (356) (822)
Change in fair value of derivative liability 48
Gain on the sale of Sysorex Arabia 23
Other income/(expense) 69 (1)
Total Other Income (Expense) (287) (752)
Net Loss from Continuing Operations (5,150) (4,532)
Loss from Discontinued Operations, Net of Tax (1,711)
Net Loss (5,150) (6,243)
Net Income/(Loss) Attributable to Non-controlling Interest (5)
Net Loss Attributable to Stockholders of Inpixon (5,145) (6,243)
Deemed dividend to preferred stockholders (1,508)
Deemed dividend for triggering of warrant down round feature (1,250)
Net Loss Attributable to Common Stockholders $ (6,395) $ (7,751)
Net Loss Per Basic and Diluted Common Share    
Loss from continuing operations $ (1.42) $ (57.57)
Loss from discontinued operations (16.31)
Net Loss Per Share - Basic and Diluted $ (1.42) $ (73.88)
Weighted Average Shares Outstanding    
Basic and Diluted 4,495,536 104,915